CE: HER2-Positive Metastatic Breast Cancer and What Targeted Therapy Means for Managed Care

February 27, 2021
Directions in Pharmacy, February 2021, Volume 3, Issue 1

This activity is supported by educational grants from Seagen Inc., Daiichi Sankyo, and AstraZeneca.

This activity is supported by educational grants from Seagen Inc., Daiichi Sankyo, and AstraZeneca.

EDUCATIONAL OBJECTIVES

At the completion of this activity, the participant will be able to:

  • Analyze evolving guideline recommendations for patient management in the treatment of HER2+ metastatic breast cancer.
  • • Identify financial considerations associated with HER2+ metastatic breast cancer and the impact of therapy on patient care.

FACULTY

Laura Bobolts, PharmD, BCOP

Senior Vice President , Clinical Strategy and Growth

Oncology Analytics, Inc, Plantation, Florida

Kelly Gaertner, PharmD, BCOP, BCPS

Oncology Clinical Pharmacy Specialist

Allegheny Health Network Cancer Institute, Pittsburgh, Pennsylvania

Philip Schwieterman, PharmD, MHA

Director of Oncology and Pediatric Pharmacy

UK HealthCare, Lexington, Kentucky

TARGET AUDIENCE: Oncology pharmacists, managed care pharmacists

ACTIVITY TYPE: Application

RELEASE DATE: February 15, 2021

EXPIRATION DATE: August 15, 2021

ESTIMATED TIME TO COMPLETE ACTIVITY: 1 hour

FEE: This lesson is offered for free at www.pharmacytimes.org.